SDSU Researchers Identify Rare Genetic Markers of Drug-Resistant Tuberculosis
Search for rare mutations in bacterial genome could lead to better diagnostics and treatments reducing morbidity caused by the deadly disease.
To many, tuberculosis (TB) may seem like a disease from a bygone era. But it still claims more than one million lives every year. And the problem is growing worse as Mycobacterium tuberculosis, the pathogen that causes TB, continues to evolve resistance to the antibiotics used to treat the disease.
Now, researchers at San Diego State University and their colleagues have identified rare genetic markers in M. tuberculosis that could improve early detection of drug-resistant strains of the disease, helping prevent their spread.
To test whether someone has a strain of TB that will no longer respond to standard treatment, clinicians culture samples of mucus from the respiratory tract and barrage them with antibiotics.
“But because TB grows so slowly, that takes weeks,” said Faramarz Valafar, a professor of public health. “In those weeks that patient is going around spreading TB that might be antibiotic-resistant.”
He says molecular diagnostic tools are much faster. These test for common genetic markers of drug resistance and allow for more timely treatment. But TB strains with rare mechanisms of resistance — lacking the common genetic markers — still elude molecular detection.
This leads clinicians to incorrectly conclude that standard TB drugs will kill the bacteria. “And so the patient is given the wrong medications and continues to infect others for weeks — sometimes months — before they realize that these drugs aren't working. So we really want to prevent that.”
Derek Conkle-Gutierrez, a doctoral student in Valafar’s lab, led the search for rare genetic mutations associated with resistance. The researchers obtained samples of M. tuberculosis from seven countries where antibiotic resistance is common. Culturing the samples revealed some were indeed drug-resistant, even though molecular diagnostics had failed to catch them.
“First we confirmed that they didn't have the known markers and then we started looking for what other mutations are showing up exclusively in these unexplained resistant isolates,” said Conkle-Gutierrez.
The researchers identified one set of rare genetic mutations that is known to block the common TB drug kanamycin from interfering with the pathogen’s ability to synthesize the proteins it needs, rendering it harmless to the pathogen. Another set of mutations may do the same for the TB drug capreomycin.
The study was supported by a grant from the National Institute of Allergy and Infectious Diseases (NIAID) and is published in the journal Antimicrobial Agents and Chemotherapy.
Next steps
“This manuscript identifies potential markers; confirmatory work for the selection of markers for the next generation of more comprehensive molecular diagnostic platforms lies ahead,” said Valafar.
He says given the evolution of antibiotic resistance, molecular diagnostics will need to be updated frequently and be tailored to different regions of the world where antibiotic resistance in TB is common. Conkle-Gutierrez agrees.
“The practice of going in and really looking for these unexplained cases, bringing them in, sequencing them, is a large, expensive project, but it needs to be done in order to find these rare cases so that they don't slip through the cracks and spread, causing more antibiotic resistance that just goes undetected.”
As researchers learned during the 20th century, the widespread use of lifesaving antibiotics may have transformed medicine, but bacterial pathogens, like M. tuberculosis, quickly evolved resistance. That’s because the strains of bacteria that survive the onslaught of these powerful drugs harbor mutations that allow them to persist and multiply in number. This is exacerbated by the use of antibiotics in livestock and for non-bacterial infections in humans, such as those caused by viruses.
Close to home
It’s estimated that about a quarter of the world’s population is infected with TB, which has two phases: latent and active. Most people stay in the latent phase, symptom-free and are not contagious, as their immune systems keep the bacterial load in check. . About 10% of those infections convert into active TB. Patients then experience symptoms and can spread the disease to others.
“It is a very important public health concern for the United States as well,” said Valafar, who says many people in this country have latent TB. “The fear is that other pulmonary infections like COVID could overwhelm the immune system and trigger TB to go into its active phase. If this happens, TB will become a bigger problem in the Western world as well. We have already seen this in HIV co-infections. (From 2020: COVID-19 Could Activate Latent Tuberculosis)”
Ultimately, an effective vaccine for TB is sorely needed. Until then, improving molecular diagnostics for the detection of antibiotic resistance is important for controlling morbidity. To this end, Valafar’s lab has recently received another grant from the National Institute of Allergy and Infectious Diseases to directly sequence drug-resistant TB from infected lung tissue.
“And that will really break through some barriers that the tuberculosis research community has been facing,” he said.
